By Barry Wilson
On March 26, 2012, the U.S. Supreme Court issued a much anticipated GVR (grant [certiorari], vacate and remand) order in the Association for Molecular Pathology v. the United States Patent Office (a.k.a. ACLU v. Myriad), remanding the case to the Federal Circuit for reevaluation in light of the Supreme Courts’ recent decision in Mayo Medical Laboratories v. Prometheus Laboratories 566 U.S. ____ (US 2012). The Prometheus decision has been extensively discussed in the media but its possible impact on the Federal Circuit decision in Myriad has received much less attention.
Click here to read the entire article as published by Law360.